glp 1 peer reviewed articles Glucagon-like peptide in health and disease Dietary intake by patients taking

Agonistas del receptor GLP-1 presentan efectos secundarios raros Noticiero Medico 1 feb 2024 3 min de lectura La aprobacin del agonista del receptor de GLP-1 semaglutida para la regulacin del peso en enero de 2023 marc el comienzo de una nueva era en el tratamiento de la obesidad

Plasma cholesteryl ester protein

[DOI] [PMC free article] [PubMed] [Google Scholar] 30.Griffiths K.K., Levy R.J

The semaglutide group showed a significantly improved Kansas City Cardiomyopathy Questionnaire clinical summary score and a longer 6-min walking distance from baseline (21.5 m and 1.2 m in the semaglutide and placebo groups, respectively, intergroup difference 20.3 m, 95% CI 8.632.1 m), compared with that in the placebo group despite the relatively short observation period of 52 weeks

aHR: 0.88, 95% CI: 0.800.96) and MAKEs (10.8% vs